Mesoblast (MESO) said late Wednesday that its Ryoncil mesenchymal stromal cell therapy is now available for purchase in the US.

Ryoncil is approved for treatment of pediatric patients aged two months and above, including adolescents and teenagers, with steroid-refractory acute graft versus host disease, a condition with high mortality rates.

The company said it will sign a national drug rebate agreement with Medicaid and expects to be enrolled in the program in short order.